These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 24575888)

  • 1. Asymmetric synthesis of the HMG-CoA reductase inhibitor atorvastatin calcium: an organocatalytic anhydride desymmetrization and cyanide-free side chain elongation approach.
    Chen X; Xiong F; Chen W; He Q; Chen F
    J Org Chem; 2014 Mar; 79(6):2723-8. PubMed ID: 24575888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly stereoselective hydrogenations--as key-steps in the total synthesis of statins.
    Andrushko N; Andrushko V; Tararov V; Korostylev A; König G; Börner A
    Chirality; 2010 May; 22(5):534-41. PubMed ID: 19899159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An efficient synthesis of N3,4-diphenyl-5-(4-fluorophenyl)-2-isopropyl-1H-3-pyrrolecarboxamide, a key intermediate for atorvastatin synthesis.
    Pandey PS; Srinivasa Rao T
    Bioorg Med Chem Lett; 2004 Jan; 14(1):129-31. PubMed ID: 14684313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors.
    Park WK; Kennedy RM; Larsen SD; Miller S; Roth BD; Song Y; Steinbaugh BA; Sun K; Tait BD; Kowala MC; Trivedi BK; Auerbach B; Askew V; Dillon L; Hanselman JC; Lin Z; Lu GH; Robertson A; Sekerke C
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1151-6. PubMed ID: 18155906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Facile preparation of monodisperse pharmaceutical colloidal spheres of atorvastatin calcium via self-assembly.
    Zhang HX; Zhao H; Wang JX; Chen JF; Lu YF; Yun J
    Small; 2009 Aug; 5(16):1846-9. PubMed ID: 19415652
    [No Abstract]   [Full Text] [Related]  

  • 6. Streamlined catalytic asymmetric synthesis of atorvastatin.
    Kawato Y; Chaudhary S; Kumagai N; Shibasaki M
    Chemistry; 2013 Mar; 19(12):3802-6. PubMed ID: 23436316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipophilic nature of atorvastatin.
    Stolley SN; Ito MK
    Am J Health Syst Pharm; 1999 Oct; 56(19):1988-9. PubMed ID: 10554920
    [No Abstract]   [Full Text] [Related]  

  • 8. Atorvastatin calcium: an addition to HMG-CoA reductase inhibitors.
    Chong PH; Seeger JD
    Pharmacotherapy; 1997; 17(6):1157-77. PubMed ID: 9399600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The discovery and development of atorvastatin, a potent novel hypolipidemic agent.
    Roth BD
    Prog Med Chem; 2002; 40():1-22. PubMed ID: 12516521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro availability of atorvastatin in presence of losartan.
    Arayne MS; Sultana N; Haroon U; Qureshi F; Ali SA
    Pak J Pharm Sci; 2006 Apr; 19(2):134-41. PubMed ID: 16751125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase.
    Bratton LD; Auerbach B; Choi C; Dillon L; Hanselman JC; Larsen SD; Lu G; Olsen K; Pfefferkorn JA; Robertson A; Sekerke C; Trivedi BK; Unangst PC
    Bioorg Med Chem; 2007 Aug; 15(16):5576-89. PubMed ID: 17560788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hypercholesterolemia.
    Pfefferkorn JA; Choi C; Larsen SD; Auerbach B; Hutchings R; Park W; Askew V; Dillon L; Hanselman JC; Lin Z; Lu GH; Robertson A; Sekerke C; Harris MS; Pavlovsky A; Bainbridge G; Caspers N; Kowala M; Tait BD
    J Med Chem; 2008 Jan; 51(1):31-45. PubMed ID: 18072721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process.
    Kim MS; Jin SJ; Kim JS; Park HJ; Song HS; Neubert RH; Hwang SJ
    Eur J Pharm Biopharm; 2008 Jun; 69(2):454-65. PubMed ID: 18359211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure elucidation and enantioselective total synthesis of the potent HMG-CoA reductase inhibitor FR901512 via catalytic asymmetric Nozaki-Hiyama reactions.
    Inoue M; Nakada M
    J Am Chem Soc; 2007 Apr; 129(14):4164-5. PubMed ID: 17367147
    [No Abstract]   [Full Text] [Related]  

  • 15. Binding thermodynamics of statins to HMG-CoA reductase.
    Carbonell T; Freire E
    Biochemistry; 2005 Sep; 44(35):11741-8. PubMed ID: 16128575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: a bench-to-bedside case study on tissue selective drug distribution.
    Pfefferkorn JA; Litchfield J; Hutchings R; Cheng XM; Larsen SD; Auerbach B; Bush MR; Lee C; Erasga N; Bowles DM; Boyles DC; Lu G; Sekerke C; Askew V; Hanselman JC; Dillon L; Lin Z; Robertson A; Olsen K; Boustany C; Atkinson K; Goosen TC; Sahasrabudhe V; Chupka J; Duignan DB; Feng B; Scialis R; Kimoto E; Bi YA; Lai Y; El-Kattan A; Bakker-Arkema R; Barclay P; Kindt E; Le V; Mandema JW; Milad M; Tait BD; Kennedy R; Trivedi BK; Kowala M
    Bioorg Med Chem Lett; 2011 May; 21(9):2725-31. PubMed ID: 21183342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-dimensional quantitative structure (3-D QSAR) activity relationship studies on imidazolyl and N-pyrrolyl heptenoates as 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) inhibitors by comparative molecular similarity indices analysis (CoMSIA).
    Thilagavathi R; Kumar R; Aparna V; Sobhia ME; Gopalakrishnan B; Chakraborti AK
    Bioorg Med Chem Lett; 2005 Feb; 15(4):1027-32. PubMed ID: 15686906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of oral bioavailability of atorvastatin calcium by self-emulsifying drug delivery systems (SEDDS).
    Kadu PJ; Kushare SS; Thacker DD; Gattani SG
    Pharm Dev Technol; 2011 Feb; 16(1):65-74. PubMed ID: 20088679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asymmetric Synthesis of Vitamin D3 Analogues: Organocatalytic Desymmetrization Approach toward the A-Ring Precursor of Calcifediol.
    Wang H; Yan L; Wu Y; Lu Y; Chen F
    Org Lett; 2015 Nov; 17(21):5452-5. PubMed ID: 26507192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DFT study on hydroxy acid-lactone interconversion of statins: the case of atorvastatin.
    Hoffmann M; Nowosielski M
    Org Biomol Chem; 2008 Oct; 6(19):3527-31. PubMed ID: 19082153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.